PubMed Health⌕ Search

Biomedical subjects

U Bier

Publications and source records attributed to U Bier.

6 recordsLinked to original sources
PubMed2006

[Antibiotic prophylaxis in cesarean section -- piperacillin versus piperacillin/tazobactam in 300 cesarean sections].

INTRODUCTION: Antibiotic prophylaxis is a standard procedure in obstetric surgery and has been discussed in various investigations. Use of treatment is judged by high efficacy and good tolerance. METHOD: In 300 patients undergoing cesarean sections we compared results of application of Piperacillin 4 g and Piperacillin/Tazobactam 4.5 g after cut of umbilical cord. Tazobactam/Piperacillin is a combination of a broad-spectrum penicillin and a beta-lactamase inhibitor with increased toxicity against staph. aureus, enterobacter, and other germs responsible for local and systemic infections in obstetric surgery. RESULTS: We did not observe any severe adverse effects. Rate of severe wound infections was 1.3 % (Tazobactam/Piperacillin) and 2 % (Piperacillin alone). The difference showed no statistic significance (p > 0.01). During postoperative course we found a higher increase of CRP (p < 0.01) in the Piperacillin group. CRP proved to be a useful objective parameter to distinguish between patients with or without postoperative infections. No differences were found in the number of leucocytes, time in hospital and other parameters.

Anti-Bacterial Agents↗
PubMed1999

A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel.

OBJECTIVES: To determine the effect of two low-dose monophasic oral contraceptives containing either 2 mg chlormadinone acetate or 150 microg desogestrel on blood clotting and fibrinolysis. METHODS: In vivo markers of intravascular coagulatory and fibrinolytic activity were measured in 45 volunteers randomly assigned to a 6-month treatment with one of the two study preparations. RESULTS: During oral contraceptive use, the procoagulatory activity increased (increased prothrombin fragment 1+2), the anticoagulatory capacity changed (increased protein C activity, decreased activated protein C sensitivity, decreased protein S activity and decreased antithrombin III activity) and the fibrinolytic system was activated (increased concentrations of plasmin-antiplasmin complexes and D-dimer as well as total fibrin degradation products). There were no relevant differences between the two medication groups. CONCLUSION: Our results demonstrate that both oral contraceptive preparations have comparable effects on the hemostatic system. There was a shift towards a new equilibrium of hemostatic activities, both coagulatory and fibrinolytic, at a higher turnover rate. Changes did not exceed the range of normal variation and were comparable to the published effects of other low-dose oral contraceptives. There was no evidence ofa differential risk of deep vein thrombosis between the two preparations.

Adolescent↗
PubMed1997

[A method for true nose lengthening].

There are various methods of lengthening the nose after trauma or for congenitally short noses. Forehead flaps and bone and cartilage grafts to the nasal dorsum are routinely performed. Bone grafts to the dorsum are onlay grafts that can show resorption. In craniofacial procedures, e.g., after Le Fort II/III osteotomies, the nose is brought forward and downward as necessary. This principle for nasal lengthening has been applied to 11 patients with congenitally short noses or after trauma. A coronal incision was made, an extensive subperiosteal skin undermining above the entire nasal bones and the piriform aperture was performed. Then a naso-frontal osteotomy was carried out, which runs downward to the piriform aperture. It runs either anteriorly to the lacrimal sac or it runs behind it through the medial orbital wall. It then crosses the inferior orbital rim and runs from there into the nasal floor. The nasal lining is released and the osteotomized fragment mobilized and moved caudally and anteriorly. This results in a deviation of the nasal septum, requiring a septoplasty. Cranial bone grafts (outer table) are interposed in the osteotomy gaps and fixed with microplates. This method of nose lengthening was applied to 11 patients with good results.

Adult↗
PubMed1996

[Effectiveness and tolerance of Navoban (5HT3-receptor antagonist tropisetron) in prevention of cytostatic drug-induced nausea and vomiting in patients with breast carcinomas and gynecological malignancies].

Efficacy and safety of the antiemetic agent Navoban (5HT3-receptor-antagonist Tropisetron) on cytostatic-induced emesis of breast cancers and gynecological cancers was tested in 28 female patients receiving a total of 127 chemotherapy courses containing high (cisplatin), moderate high (cyclophosphamid) or moderate (for example 5 FU) emetogenic cytostatic drugs. We studied antiemetic response rates of Navoban (5 mg/d) during the first 24 hours after administration of the chemotherapy as well as response rates of the "delayed nausea and emesis" (days 2-9 after chemotherapy). A complete response was observed in 103 chemotherapy courses (= 81.1%) during the first 24 hours after chemotherapy and in 93 courses (= 73.2%) for the "delayed emesis". Treatment failures (more than 5 vomiting episodes) during the first 24 hours were present in four courses and for the "delayed emesis" in 11 courses. The side effects of Navoban such as constipation, headache or tiredness were minimum. Therefore no patient refused to receive the necessary chemotherapy. Navoban is, with its single dose application, an effective therapeutic drug for the prevention of nausea and emesis in patients receiving a chemotherapy.

Adult↗
PubMedDate not supplied

Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate: an open, randomized, parallel-group study.

OBJECTIVE: To determine effects on blood clotting of two modern low-dose monophasic oral contraceptives. SUBJECTS AND METHODS: We measured in vivo markers of intravascular coagulatory and fibrinolytic activity in 40 volunteers randomly assigned to one of two low-dose oral contraceptives (OCs) for 6 months; one contained 35 micrograms of ethinyl estradiol (EE) plus 250 micrograms of norgestimate and the other, 30 micrograms of EE plus 75 micrograms of gestodene. RESULTS: Both formulations increased coagulatory as well as fibrinolytic activity over baseline: circulating reactive products of thrombin increased by 40%, and plasmin activity by 60%, after 3 months of treatment. Six months of OC use increased hemostatic activity substantially over that with 3 months of use. Differences between both OC formulations were marginal and clinically insignificant. CONCLUSION: The data suggest an EE-dose-dependent, balanced activation of in vivo coagulation and fibrinolysis in users of currently available, combined OCs. However, there is considerable consumption of coagulation inhibiting factors, suggesting that women with congenital deficiencies of antithrombin III and protein C should not use combined OCs.

Adult↗